Zolunicant hydrochloride is under clinical development by Mind Medicine MindMed and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Zolunicant hydrochloride’s likelihood of approval (LoA) and phase transition for Opium (Opioid) Addiction took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zolunicant hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Zolunicant hydrochloride overview

18-Methoxycoronaridine (18-MC) is under development for the treatment of leishmaniasis, substance addictions including cocaine, opiate, methamphetamine, nicotine, alcohol and opioid use disorders. The drug candidate is administered orally. The drug candidate is an alpha-3-beta-4 nicotinic receptor antagonist. It is a new chemical entity.

It was also under development for the treatment of obesity, other forms of compulsive behavior. It is a psychedelic drug.

Mind Medicine MindMed overview

Mind Medicine MindMed (MindMed) is a neuro-pharmaceutical company. It develops, discovers and deploys psychedelic inspired medicines to promote wellness, improve health, and alleviate suffering. MindMed is headquartered in New York, the US.

Quick View Zolunicant hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Zolunicant hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.